Rajesh Karan
Overview
Explore the profile of Rajesh Karan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pagano G, Dam T, Kerchner G, Galpern W, Biagioni M, Karan R, et al.
NPJ Parkinsons Dis
. 2024 Dec;
10(1):235.
PMID: 39706882
No abstract available.
2.
Krupp L, Banwell B, Chitnis T, Deiva K, Gaertner J, Ghezzi A, et al.
BMJ Neurol Open
. 2022 Mar;
4(1):e000215.
PMID: 35308898
Background: In the PARADIG Study, fingolimod demonstrated superior efficacy versus interferon (IFN) β-1a and comparable overall incidence of adverse events but slightly higher rate of serious adverse events in patients...
3.
Sivasubramanian R, Sunkara G, Karan R, Zhou W, Zhang Y, Sangana R
Clin Pharmacol Drug Dev
. 2022 Jan;
11(7):843-848.
PMID: 35050548
The bioequivalence of valsartan 160 mg oral solution compared to suspension was assessed in a single-dose, open-label, randomized, 2-period, 2-way crossover study in 82 healthy adults. The participants were randomly...
4.
Reinhardt F, Scarmeas N, Karan R, Veldandi U, Modali S, Duvvuri K, et al.
Curr Alzheimer Res
. 2021 Jul;
18(4):273-282.
PMID: 34279198
Background: Transdermal patches are convenient to use, especially in Rotkreuz ZG Rotkreuz ZG patients with Alzheimer's disease (AD)-associated dementia. However, various identified risks of errors in administering the patches cannot...
5.
Cree B, Goldman M, Corboy J, Singer B, Fox E, Arnold D, et al.
JAMA Neurol
. 2020 Aug;
PMID: 32852530
Importance: Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety...
6.
Chitnis T, Banwell B, Krupp L, Arnold D, Bar-Or A, Bruck W, et al.
Mult Scler
. 2020 Jul;
27(6):922-932.
PMID: 32633694
Background: Reduction in absolute lymphocyte count (ALC) is expected with fingolimod treatment. Objective: To evaluate the effect of fingolimod 0.5 mg versus intramuscular interferon β-1a (30 μg) on ALC and...
7.
Moore R, Derry S, Wiffen P, Banerjee S, Karan R, Glimm E, et al.
Pain
. 2018 Jul;
159(11):2234-2244.
PMID: 29965830
Network meta-analysis uses direct comparisons of interventions within randomized controlled trials and indirect comparisons across them. Network meta-analysis uses more data than a series of direct comparisons with placebo, and...
8.
Duan J, Chen J, Yin Q, Karan R, Meiser K, Smith H, et al.
Int J Clin Pharmacol Ther
. 2011 Dec;
50(1):33-43.
PMID: 22192643
Objective: The efficacy and safety of valsartan/amlodipine combination have been demonstrated for the treatment of hypertension. In China, where the prevalence of hypertension is increasing the pharmacokinetic study of valsartan,...
9.
Bhad P, Ayalasomayajula S, Karan R, Leon S, Riviere G, Sunkara G, et al.
J Clin Pharmacol
. 2010 Sep;
51(6):933-42.
PMID: 20852001
The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort,...